Skin and Joints Podcast

Melinda Knows Best: AAD 2025 Orlando Hands Up with Dr.Melinda Gooderham

Episode Summary

🙌 Hands Down at AAD 2025: Delgocitinib and the “Super-Responder” Story 🌴🎧 🐶✨ Puppies in the hall, Snoop after dark, and a late-breaker that might change how you treat chronic hand eczema on Monday. In this AAD 2025 mini-episode of our “Melinda Knows Best” series, Dr. Melinda Gooderham unpacks a fresh subgroup analysis from the DELTA 1/2/3 program in chronic hand eczema (CHE)—what a “super responder” actually is, how long clearance can last off-therapy, and where a non-steroidal topical like delgocitinib could fit for real patients with real lives (and real world adherence). 🖐️🧴 Why queue this up? 🔥 Because it’s rare to get practice-ready signals for CHE: about half of patients hit at least one deep patient-reported threshold by Week 16, and—here’s the eye-opener—after stopping therapy at Week 16, ~⅓ were still clear/almost clear at 8 weeks and ~15% at 12 weeks. 📊⏱️ 🎯 What you’ll learn: 🧭Define “super responder” in CHE via three lenses: 📝Read the right scales fast: quick-hit use of HESD, HECSI, and IGA-CHE—and how to translate them into patient-friendly goals. ⏳Set expectations on durability: what “clear/almost clear” really means (that IGA-CHE bar is high) and how to discuss planned pauses without fueling steroid-withdrawal anxiety. 🧴Position a topical, non-steroidal JAK inhibitor thoughtfully: where a topical, non-steroidal JAK inhibitor can slot alongside—or instead of—steroids/phototherapy in moderate–severe CHE, especially for adherence-sensitive hands. 🔁Bridge trials to the clinic rooms: a simple CHE workflow (start → measure → decide → pause → rescue → re-start) anchored to PROs and signs you can track in under 60 seconds. 🔊 Teaser sound bites “Not all ‘super responders’ are the same—PROs, consistency, and maintenance tell different parts of the story.” 🎯 “Clear/almost clear on IGA-CHE is a stringent bar—set it, explain it, and celebrate it.” ✅ 🎙️ Hit play for late-breaker highlights🌴😅 #AAD2025 #Dermatology #ChronicHandEczema #CHE #Delgocitinib #TopicalJAK #JAKInhibitors #EczemaCare #HECSI #HESD #IGACHE #PROs #LateBreaker #EvidenceBased #HCP #Derms #GPs #SkinAndJointsPodcast #MelindaKnowsBest #Orlando ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology) Toronto, ON Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases. 📻www.skinandjoints.ca ✉️info@skinandjoints.ca

Episode Notes

🙌 Hands Down at AAD 2025: Delgocitinib and the “Super-Responder” Story 🌴🎧

🐶✨ Puppies in the hall, Snoop after dark, and a late-breaker that might change how you treat chronic hand eczema on Monday. In this AAD 2025 mini-episode of our “Melinda Knows Best” series, Dr. Melinda Gooderham unpacks a fresh subgroup analysis from the DELTA 1/2/3 program in chronic hand eczema (CHE)—what a “super responder” actually is, how long clearance can last off-therapy, and where a non-steroidal topical like delgocitinib could fit for real patients with real lives (and real world adherence). 🖐️🧴

Why queue this up? 🔥 Because it’s rare to get practice-ready signals for CHE: about half of patients hit at least one deep patient-reported threshold by Week 16, and—here’s the eye-opener—after stopping therapy at Week 16, ~⅓ were still clear/almost clear at 8 weeks and ~15% at 12 weeks. 📊⏱️

🎯 What you’ll learn:

🧭Define “super responder” in CHE via three lenses:
📝Read the right scales fast: quick-hit use of HESD, HECSI, and IGA-CHE—and how to translate them into patient-friendly goals.
⏳Set expectations on durability: what “clear/almost clear” really means (that IGA-CHE bar is high) and how to discuss planned pauses without fueling steroid-withdrawal anxiety.
🧴Position a topical, non-steroidal JAK inhibitor thoughtfully: where a topical, non-steroidal JAK inhibitor can slot alongside—or instead of—steroids/phototherapy in moderate–severe CHE, especially for adherence-sensitive hands.
🔁Bridge trials to the clinic rooms: a simple CHE workflow (start → measure → decide → pause → rescue → re-start) anchored to PROs and signs you can track in under 60 seconds.

🔊 Teaser sound bites

“Not all ‘super responders’ are the same—PROs, consistency, and maintenance tell different parts of the story.” 🎯
“Clear/almost clear on IGA-CHE is a stringent bar—set it, explain it, and celebrate it.” ✅

🎙️ Hit play for late-breaker highlights🌴😅

#AAD2025 #Dermatology #ChronicHandEczema #CHE #Delgocitinib #TopicalJAK #JAKInhibitors #EczemaCare #HECSI #HESD #IGACHE #PROs #LateBreaker #EvidenceBased #HCP #Derms #GPs #SkinAndJointsPodcast #MelindaKnowsBest #Orlando

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca